What is Eylea and Eylea HD?
Eylea (aflibercept) is an FDA-approved anti-VEGF injection for treating wet age-related macular degeneration (AMD), diabetic macular edema (DME), and other retinal conditions by blocking vascular endothelial growth factor to reduce abnormal blood vessel growth.[1] Eylea HD (aflibercept 8 mg) is a higher-dose version of the same drug, approved in August 2023 for similar indications like wet AMD, DME, and diabetic retinopathy.[1][2]
Key Formulation Differences
Eylea contains 2 mg of aflibercept per 0.05 mL dose, while Eylea HD has 8 mg per 0.07 mL dose—four times the strength.[1][2] Both use the same active ingredient but Eylea HD includes a higher concentration to enable less frequent dosing without increasing injection volume significantly.[2]
Dosing Schedules Compared
Standard Eylea requires injections every 4-12 weeks after initial loading doses, depending on the condition.[1] Eylea HD supports extended intervals: every 12-16 weeks for wet AMD and DME after three initial monthly doses, and every 8-12 weeks for diabetic retinopathy.[2] This reduces treatment burden—patients may need up to 4 fewer injections per year.[1][2]
| Aspect | Eylea (2 mg) | Eylea HD (8 mg) |
|--------|--------------|-----------------|
| Wet AMD | Loading: 3 monthly, then every 8 weeks (can extend to 12) | Loading: 3 monthly, then every 12 weeks (can extend to 16) |
| DME | Loading: 5 monthly, then every 8-12 weeks | Loading: 3 monthly, then every 12 weeks (can extend to 16) |
| Volume per dose | 0.05 mL | 0.07 mL |
Efficacy and Clinical Trial Data
In the PULSAR (wet AMD) and PHOTON (DME) trials, Eylea HD matched or exceeded Eylea 2 mg in vision improvement (best-corrected visual acuity gains of 9-10 letters) while allowing longer intervals.[2] About 80% of wet AMD patients and 73% of DME patients on Eylea HD maintained 12-16 week dosing through year one.[2] No new safety signals emerged despite the higher dose.[1][2]
Safety and Side Effects
Both share common risks like eye inflammation, cataracts, increased intraocular pressure, and rare endophthalmitis from injection.[1][2] Eylea HD trials showed comparable rates to Eylea, with no increase in vascular events or retinal issues linked to the dose.[2] It's contraindicated in active eye infections.
Cost and Availability
Eylea HD lists at about $1,980 per dose, similar to Eylea, but fewer injections may lower annual costs (e.g., $10,000-$15,000 vs. $15,000+ for Eylea).[3] Covered by most insurance for approved uses; patient assistance programs exist via Regeneron.[3] Eylea HD launched in late 2023.[2]
Who Makes Them and Patent Status?
Regeneron Pharmaceuticals and Bayer co-develop and market both globally.[1] Eylea faces biosimilar challenges, with patents expiring around 2023-2027 in major markets; check DrugPatentWatch.com for U.S. details on Paragraph IV challenges and expiry timelines.[4]
[1]: FDA Label - Eylea (https://www.accessdata.fda.gov/drugsatfdadocs/label/2023/125387s280lbl.pdf)
[2]: FDA Label - Eylea HD (https://www.accessdata.fda.gov/drugsatfdadocs/label/2023/761275s000lbl.pdf)
[3]: Regeneron Pricing Info (https://www.regeneron.com/patients/eylea-hd)
[4]: DrugPatentWatch - Eylea (https://www.drugpatentwatch.com/p/tradename/EYLEA)